A detailed history of Price T Rowe Associates Inc transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 13,357 shares of PBYI stock, worth $36,731. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,357
Previous 13,357 -0.0%
Holding current value
$36,731
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.92 - $5.83 $39,002 - $77,871
13,357 New
13,357 $0
Q2 2022

Aug 15, 2022

SELL
$1.64 - $3.3 $4,703 - $9,464
-2,868 Reduced 5.94%
45,400 $129,000
Q1 2022

May 16, 2022

BUY
$2.13 - $3.24 $72,207 - $109,836
33,900 Added 235.94%
48,268 $139,000
Q4 2021

Feb 14, 2022

SELL
$2.85 - $6.58 $855 - $1,974
-300 Reduced 2.05%
14,368 $44,000
Q2 2021

Aug 16, 2021

BUY
$8.98 - $11.6 $5,774 - $7,458
643 Added 4.58%
14,668 $135,000
Q1 2021

May 17, 2021

SELL
$9.38 - $13.63 $150 - $218
-16 Reduced 0.11%
14,025 $136,000
Q4 2020

Feb 16, 2021

BUY
$7.78 - $12.13 $109,238 - $170,317
14,041 New
14,041 $144,000

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $125M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.